These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 23320989)

  • 1. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
    Citrome L
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):193-206. PubMed ID: 23320989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):102-13. PubMed ID: 23361832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.
    Veselinović T; Paulzen M; Gründer G
    Expert Rev Neurother; 2013 Nov; 13(11):1141-59. PubMed ID: 24175719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.
    Nasrallah HA; Earley W; Cutler AJ; Wang Y; Lu K; Laszlovszky I; Németh G; Durgam S
    BMC Psychiatry; 2017 Aug; 17(1):305. PubMed ID: 28836957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cariprazine for acute and maintenance treatment of schizophrenia].
    Spoelstra SK; Visser L; Knegtering H
    Tijdschr Psychiatr; 2019; 61(10):702-709. PubMed ID: 31907914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment).
    Nakamura T; Kubota T; Iwakaji A; Imada M; Kapás M; Morio Y
    Drug Des Devel Ther; 2016; 10():327-38. PubMed ID: 26834462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Cariprazine and its Major Metabolites.
    Periclou A; Phillips L; Ghahramani P; Kapás M; Carrothers T; Khariton T
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):53-69. PubMed ID: 33141308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.
    Kane JM; Zukin S; Wang Y; Lu K; Ruth A; Nagy K; Laszlovszky I; Durgam S
    J Clin Psychopharmacol; 2015 Aug; 35(4):367-73. PubMed ID: 26075487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of cariprazine in the treatment of bipolar disorder.
    Saraf G; Pinto JV; Yatham LN
    Expert Opin Pharmacother; 2019 Dec; 20(17):2063-2072. PubMed ID: 31644326
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical potential of cariprazine in the treatment of acute mania.
    Altınbaş K; Guloksuz S; Oral ET
    Psychiatr Danub; 2013 Sep; 25(3):207-13. PubMed ID: 24048386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
    Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
    Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.
    Cutler AJ; Durgam S; Wang Y; Migliore R; Lu K; Laszlovszky I; Németh G
    CNS Spectr; 2018 Feb; 23(1):39-50. PubMed ID: 28478771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
    Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cariprazine: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.
    Ketter TA; Sachs GS; Durgam S; Lu K; Starace A; Laszlovszky I; Németh G
    J Affect Disord; 2018 Jan; 225():350-356. PubMed ID: 28843918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.